Wednesday, July 8, 2026

pharma · Multiple Myeloma · generalized myasthenia gravis · RNAC

Cartesian Therapeutics

Cartesian Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker RNAC. Primary therapeutic focus areas include Multiple Myeloma, generalized myasthenia gravis, Myasthaenia G

7495 New Horizon Way, Frederick, Maryland 21703, US HQ
2016 Founded
89 Employees
Public company Type
RNAC · NYSE Ticker
Company details
Status
Public
HQ
7495 New Horizon Way, Frederick, Maryland 21703, US
Founded
2016
Employees
89
Programs
12
Drugs
4
Patents
4
Clinical program

Descartes-11

Phase 2 · mab · Multiple Myeloma

Descartes-11 for Multiple Myeloma is a Phase 2 program (mab) at Cartesian Therapeutics with 2 ClinicalTrials.gov record(s).

Internal code DC11A

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cartesian Therapeutics
Phase
Phase 2
Modality
mab
Indication
Multiple Myeloma
Status
terminated
Trials
2

Clinical trials